Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Mallett

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical Breast Cancer|June 28, 2006
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitorsBetty A Mincey, Mei Sheng Duh, Simu K Thomas, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2019
Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase <i>δ</i> InhibitorMalcolm Begg, Chris D Edwards, J Nicole Hamblin, et al.
Journal of Medicinal Chemistry|December 20, 2019
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity TargetZoë A Henley, Augustin Amour, Nick Barton, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical Breast Cancer|June 28, 2006
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitorsBetty A Mincey, Mei Sheng Duh, Simu K Thomas, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2019
Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase <i>δ</i> InhibitorMalcolm Begg, Chris D Edwards, J Nicole Hamblin, et al.
Journal of Medicinal Chemistry|December 20, 2019
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity TargetZoë A Henley, Augustin Amour, Nick Barton, et al.
Pageof 2